Physicians' Perspective on Vaccine-Hesitancy at the Beginning of Israel's COVID-19 Vaccination Campaign and Public's Perceptions of Physicians' Knowledge When Recommending the Vaccine to Their Patients: A Cross-Sectional Study.

Anat Gesser-Edelsburg, Hiba Badarna Keywan
Author Information
  1. Anat Gesser-Edelsburg: School of Public Health and the Health and Risk Communication Lab, University of Haifa, Haifa, Israel.
  2. Hiba Badarna Keywan: School of Public Health and the Health and Risk Communication Lab, University of Haifa, Haifa, Israel.

Abstract

Because public healthcare workers (HCWs) are at the forefront of the battle against COVID-19, they must be able to provide vaccination information to their patients and respond to their anxieties and concerns. This research objectives were to (1) examine physicians' perceptions of how they received information about the Pfizer COVID-19 vaccine, their attitudes toward hesitant colleagues, and their own knowledge and self-efficacy in communicating information to their patients, and (2) to examine the public's perceptions of physicians' knowledge when recommending the COVID-19 vaccine to their patients. At the beginning of the vaccination campaign, a survey examined the attitudes of physicians in the Israeli public healthcare system ( = 295) regarding the Pfizer vaccine. In addition, the attitudes of a representative sample ( = 500) of the Israeli adult population (age 18+) were examined through interviews. Most of the participating physicians (81%) reported they had already been vaccinated or intended to be vaccinated. When asked about their reasons for vaccine hesitancy, 27% cited concerns about long-term side effects and doubts about the vaccine's effectiveness in preventing contagion. They cited system pressure and departmental norms as explanations for their eventual compliance. Moreover, they saw the system as less tolerant of hesitant physicians, while they themselves tend to be more tolerant. The results of the survey of the public showed that mostly young people (under 44) who tend to be critical believe that physicians do not have sufficient knowledge to make recommendations about the COVID-19 vaccine. The findings indicate that the health system should employ complete transparency in conveying the advantages and disadvantages of the COVID-19 vaccine to physicians. The system should be more tolerant of physicians' worries and concerns and grant legitimacy to their reservations and misgivings. Moreover, medical studies should reinforce physicians' immunological knowledge regarding vaccinations so they can help their patients make informed decisions.

Keywords

References

  1. J Law Biosci. 2021 May 19;8(1):lsab015 [PMID: 34040784]
  2. J Pediatr Nurs. 2009 Oct;24(5):433-40 [PMID: 19782902]
  3. N Engl J Med. 2021 Dec 2;385(23):2140-2149 [PMID: 34614328]
  4. J Clin Nurs. 2021 Jul 26;: [PMID: 34309114]
  5. Risk Anal. 2004 Apr;24(2):335-46 [PMID: 15078304]
  6. Lancet Infect Dis. 2022 Jan;22(1):43-55 [PMID: 34480857]
  7. J Paediatr Child Health. 2018 Mar;54(3):302-310 [PMID: 28876498]
  8. Euro Surveill. 2021 Jan;26(3): [PMID: 33478623]
  9. Soc Sci Med. 2014 Jul;112:1-11 [PMID: 24788111]
  10. Am J Public Health. 2009 Jan;99(1):24-9 [PMID: 19008501]
  11. Int J Environ Res Public Health. 2021 Mar 08;18(5): [PMID: 33800187]
  12. Infect Control Hosp Epidemiol. 2006 Jun;27(6):618-22 [PMID: 16755483]
  13. N Engl J Med. 2021 Dec 9;385(24):e83 [PMID: 34614327]
  14. Eur J Pediatr. 2019 Apr;178(4):533-540 [PMID: 30706158]
  15. Saudi Med J. 2020 Jun;41(6):645-651 [PMID: 32518933]
  16. Vaccine. 2010 Feb 25;28(9):2053-9 [PMID: 20038430]
  17. Ann Intern Med. 2021 Jun;174(6):882-885 [PMID: 33556267]
  18. Risk Manag Healthc Policy. 2020 Dec 14;13:2985-3002 [PMID: 33363422]
  19. Acta Paediatr. 2022 Jan;111(1):35-44 [PMID: 34614260]
  20. Vaccines (Basel). 2021 Feb 03;9(2): [PMID: 33546165]
  21. Vaccine. 2011 Aug 11;29(35):5963-9 [PMID: 21699950]
  22. Sci Rep. 2021 Jul 30;11(1):15531 [PMID: 34330945]
  23. Vaccine. 2006 Sep 11;24(37-39):6351-5 [PMID: 16784799]
  24. Vaccine. 2014 Aug 27;32(38):4860-5 [PMID: 24262311]
  25. Lancet. 2021 Dec 4;398(10316):2093-2100 [PMID: 34756184]
  26. N Engl J Med. 2021 Apr 15;384(15):1412-1423 [PMID: 33626250]
  27. Disaster Med Public Health Prep. 2015 Aug;9(4):447-58 [PMID: 26186579]
  28. Accid Anal Prev. 2018 Feb;111:1-11 [PMID: 29153983]
  29. Infect Control Hosp Epidemiol. 2012 Mar;33(3):243-9 [PMID: 22314061]
  30. Vaccine. 2001 Oct 15;20 Suppl 1:S5-7; discussion S1 [PMID: 11587800]
  31. J Med Internet Res. 2019 Jul 03;21(7):e14105 [PMID: 31271145]
  32. Intern Emerg Med. 2021 Apr;16(3):803-804 [PMID: 33687691]
  33. EClinicalMedicine. 2021 Feb 03;32:100746 [PMID: 33644722]
  34. Pediatr Nurs. 2016 Jan-Feb;42(1):21-30, 35 [PMID: 27019938]
  35. N Engl J Med. 2021 Nov 4;385(19):1761-1773 [PMID: 34525277]
  36. Vaccines (Basel). 2021 Jul 12;9(7): [PMID: 34358193]
  37. Am J Infect Control. 2017 Apr 1;45(4):436-439 [PMID: 28063725]
  38. Lancet Infect Dis. 2012 Aug;12(8):627-34 [PMID: 22445354]
  39. Risk Manag Healthc Policy. 2021 Jun 21;14:2553-2569 [PMID: 34188567]
  40. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2010 Dec;53(12):1298-303 [PMID: 21161481]
  41. Vaccine. 2016 Jan 27;34(5):687-695 [PMID: 26458809]
  42. Isr J Health Policy Res. 2021 Jan 26;10(1):6 [PMID: 33499905]
  43. Am J Infect Control. 2007 Feb;35(1):20-4 [PMID: 17276787]
  44. Pediatrics. 2021 Sep;148(3): [PMID: 34088762]
  45. EBioMedicine. 2021 Oct;72:103574 [PMID: 34537449]
  46. Am J Infect Control. 2014 Aug;42(8):829-33 [PMID: 24939516]
  47. Int J Environ Res Public Health. 2021 Jan 11;18(2): [PMID: 33440750]
  48. Vaccine. 2021 Jun 23;39(28):3731-3736 [PMID: 34078555]
  49. PLoS One. 2021 Sep 3;16(9):e0257109 [PMID: 34478470]
  50. J Med Internet Res. 2020 May 15;22(5):e19370 [PMID: 32392172]
  51. Am J Prev Med. 2017 Sep;53(3):e97-e104 [PMID: 28237636]
  52. Science. 1989 Dec 8;246(4935):1232-3 [PMID: 2686031]
  53. Nature. 2021 Nov;599(7886):546-548 [PMID: 34815580]
  54. Vaccine. 2017 Jan 3;35(1):164-169 [PMID: 27887795]
  55. Am J Infect Control. 2012 Sep;40(7):632-6 [PMID: 22464038]
  56. JAMA. 2007 Aug 15;298(7):743-53 [PMID: 17699008]
  57. Vaccine. 2001 Oct 15;20 Suppl 1:S13-5; discussion S1 [PMID: 11587802]
  58. Antimicrob Resist Infect Control. 2020 Sep 4;9(1):148 [PMID: 32887658]
  59. Clin Infect Dis. 2021 Nov 28;: [PMID: 34849657]
  60. Medicina (Kaunas). 2021 Jun 12;57(6): [PMID: 34204614]
  61. Occup Environ Med. 2007 Apr;64(4):223-7 [PMID: 17182640]
  62. Am J Infect Control. 1989 Aug;17(4):202-7 [PMID: 2774292]
  63. BMJ. 2009 Jul 02;339:b2651 [PMID: 19574308]
  64. Vaccines (Basel). 2021 Feb 25;9(3): [PMID: 33668923]
  65. Risk Anal. 2004 Apr;24(2):311-22 [PMID: 15078302]

MeSH Term

Adolescent
Adult
COVID-19
COVID-19 Vaccines
Cross-Sectional Studies
Humans
Immunization Programs
Israel
Physicians
Vaccines

Chemicals

COVID-19 Vaccines
Vaccines

Word Cloud

Created with Highcharts 10.0.0COVID-19vaccinephysicians'physicianssystempatientsknowledgepublicvaccinationinformationconcernsperceptionsattitudestoleranthealthcareHCWsexaminePfizerhesitantpublic'scampaignsurveyexaminedIsraeli=regardingvaccinatedhesitancycitedMoreovertendmakePhysicians'workersforefrontbattlemustableproviderespondanxietiesresearchobjectives1receivedtowardcolleaguesself-efficacycommunicating2recommendingbeginning295additionrepresentativesample500adultpopulationage18+interviewsparticipating81%reportedalreadyintendedaskedreasons27%long-termsideeffectsdoubtsvaccine'seffectivenesspreventingcontagionpressuredepartmentalnormsexplanationseventualcompliancesawlessresultsshowedmostlyyoungpeople44criticalbelievesufficientrecommendationsfindingsindicatehealthemploycompletetransparencyconveyingadvantagesdisadvantagesworriesgrantlegitimacyreservationsmisgivingsmedicalstudiesreinforceimmunologicalvaccinationscanhelpinformeddecisionsPerspectiveVaccine-HesitancyBeginningIsrael'sVaccinationCampaignPublic'sPerceptionsKnowledgeRecommendingVaccinePatients:Cross-SectionalStudyIsraelcross-sectionalstudyperspective

Similar Articles

Cited By